Pulmonx Reports Third Quarter 2026 Financial Results
Pulmonx returned to growth in Q3 2026 with worldwide revenue of $22.8 million, up 6% year-over-year on both a GAAP and constant currency basis. Losses narrowed sharply: net loss fell 40% to $8.4 million ($0.19 per share) and Adjusted EBITDA loss dropped 57% to $3.5 million, with gross margin at 76%. The company reaffirmed FY2026 revenue guidance of $90-$92 million while raising its gross margin outlook to roughly 77%, and held $52.7 million in cash at quarter-end.
Key figures
- Revenue
- 22835000
- Guidance
- FY2026 revenue $90M-$92M (reaffirmed); gross margin ~77%; operating expenses $108M-$109M incl. ~$14M stock-based compensation; cash and marketable securities expected to decrease ~$22M
- Revenue Yoy
- 6%
- Net loss
- 8394000
- Us revenue
- 14911000
- Gross margin
- 76%
- Gross profit
- 17399000
- Us revenue yoy
- 6.8%
- Net loss reduction
- 40%
- Operating expenses
- 24889000
- Adjusted ebitda loss
- 3528000
- Cash and equivalents
- 52690000
- International revenue
- 7924000
- International revenue yoy
- 5.2%
- International ex china yoy
- 8.5%
- Adjusted ebitda loss reduction
- 57%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.